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AIM
Metoprolol (a CYP2D6 substrate) is often co-prescribed with paroxetine/ﬂuoxetine (a CYP2D6 inhibitor) because the clinical
relevance of this drug–drug interaction (DDI) is still unclear. This review aimed to systematically evaluate the available evidence
and quantify the clinical impact of the DDI.
METHOD
Pubmed, Web of Science, Cochrane Library and Embase were searched for studies reporting on the effect of the DDI among adults
published until April 2018. Data on pharmacokinetics, pharmacodynamics and clinical outcomes from experimental,
observational and case report studies were retrieved. The protocol of this study was registered in PROSPERO (CRD42018093087).
RESULTS
We found nine eligible articles that consisted of four experimental and two observational studies as well as three case reports.
Experimental studies reported that paroxetine increased the AUC of metoprolol three to ﬁve times, and signiﬁcantly decreased
systolic blood pressure and heart rate of patients. Case reports concerned bradycardia and atrioventricular block due to the DDI.
Results from observational studies were conﬂicting. A cohort study indicated that the DDI was signiﬁcantly associated with the
incidence of early discontinuation of metoprolol as an indicator of the emergence of metoprolol-related side effects. In a case–
control study, the DDI was not signiﬁcantly associated with bradycardia.
CONCLUSION
Despite the contradictory conclusions from the current literature, the majority of studies suggest that the DDI can lead to adverse
clinical consequences. Since alternative antidepressants and beta-blockers with comparable efﬁcacy are available, such DDIs can
be avoided. Nonetheless, if prescribing the combination is unavoidable, a dose adjustment or close monitoring of the metoprolol-
related side effects is necessary.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Metoprolol and paroxetine/ﬂuoxetine combination may trigger a CYP2D6 mediated drug–drug interaction (DDI).
• Metoprolol and paroxetine/ﬂuoxetine co-prescription is still observed in clinical practice because the clinical relevance of
this DDI is unclear.
WHAT THIS STUDY ADDS
• Despite the conﬂicting conclusions from the current published literature, themajority of studies suggest that the DDI can
cause adverse clinical consequences.
• It is prudent to avoid the concurrent use of metoprolol and paroxetine/ﬂuoxetine because alternative and safe antidepres-
sants and beta-blockers are available. However, if the prescription of the combination is unavoidable, a dose adjustment
or close monitoring of metoprolol-related side effects is necessary.
Introduction
Cardiovascular diseases and depression are still among the
most prevalent diseases in the world and they often coincide
in patients [1–4]. This situation leads to the co-prescription
of drugs for treating these chronic illnesses. The selective
β1-blocker metoprolol is one of the preferred beta-blockers
in general practice guidelines and widely prescribed for
patients with cardiac diseases in the Netherlands, New
Zealand and US [5–10]. Meanwhile, because of the favourable
safety proﬁle, selective serotonin reuptake inhibitors (SSRIs)
such as paroxetine and ﬂuoxetine are commonly used to treat
depression in this patient population [11, 12]. There have
been several studies reporting that metoprolol and
paroxetine/ﬂuoxetine are commonly co-prescribed in clinical
practice [8, 13]. Bahar et al. reported that among all co-
prescriptions of beta-blockers with paroxetine/ﬂuoxetine
during 1994–2014 for elderly patients in the community
pharmacies in the Netherlands, 52% of them was
metoprolol-paroxetine/ﬂuoxetine combination. The num-
bers of other beta-blockers combined with paroxetine/
ﬂuoxetine were 17%, 12% and 19% for atenolol, bisoprolol
and any other beta-blockers respectively [8].
Metoprolol is mainly metabolised by oxidation in the
liver [14]. However, since the CYP2D6 enzyme is most
involved in metoprolol metabolism, strong inhibitors of
CYP2D6, such as paroxetine and ﬂuoxetine, may trigger a
drug–drug interaction (DDI) which can potentially produce
metoprolol-related toxicities due to an impaired metoprolol
clearance [15–19]. Therefore, in a drug database for a
computerised DDI surveillance system [such as G-standaard
from the ‘Royal Dutch Association for the Advancement of
Pharmacy’ (KNMP)], this DDI is ﬂagged to warn health care
providers about the potential risks. However, another drug
database for drug–drug interaction alerting system (such as
Pharmabase from the Health Base Foundation) decided not
to give a signal because of the uncertainties surrounding the
DDI [8]. The decision whether to provide a safety
alert or not for the combination has been reported to
inﬂuence the number of metoprolol and paroxetine/ﬂuoxetine
co-prescriptions [8]. Consequently, the potential metoprolol-
related side effects due to the DDI are not always prevented by
the presence of DDI alerts. Hence, it is important to determine
the clinical relevance of the DDI.
In the current study, we therefore aimed to evaluate all
published studies regarding the clinical impact of the
concurrent use of metoprolol and paroxetine/ﬂuoxetine and
to quantify potential risks. In addition, we aimed to
formulate recommendations on how to manage this DDI in
the clinic.
Methods
This study was reported based on the PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-analyses)
guideline [20]. The study protocol was registered in
PROSPERO under number CRD42018093087 (www.crd.
york.ac.uk). This systematic review only included experi-
mental or observational studies and case reports (without
language restrictions) conducted among adults. In addition,
articles were included if they (1) concerned a metoprolol
and paroxetine/ﬂuoxetine combination and (2) reported
the outcomes of the interaction. We excluded conference
abstracts, reviews/editorials/letters as well as in vitro and an-
imal studies.
Search strategy
Original studies about the metoprolol and paroxetine/
ﬂuoxetine interaction were systematically searched. Pubmed,
Web of Science, Cochrane library (limited to clinical trials)
and Embase databases were used to identify articles published
before April 1, 2018. Search terms included metoprolol,
paroxetine, ﬂuoxetine, pharmacokinetics (PK) or pharmaco-
dynamics (PD) parameters, or other relevant outcomes (such
as dose adjustment or early discontinuation of metoprolol
after the start of the combination). The search queries are
available in the Supporting Information Data S1. Records
from all databases were exported to a web-based reference
manager, RefWorks, and duplicate records were removed.
Record selection
Titles and abstracts from the unique records were screened by
two reviewers independently (MAB and JK) to identify
eligible articles. In case of disagreement, discussion to
achieve consensus was initiated, and if necessary, a third
reviewer was involved (BW). After the initial title and abstract
screening, full texts from the eligible records were evaluated
also independently by MAB and JK to come to a ﬁnal selec-
tion. The level of inter-rater agreement was calculated by
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using a percentage of agreement and reliability Cohen’s
kappa (ĸ) statistic.
Data extraction
Selected articles were used to extract data on study design,
study population, metoprolol and paroxetine/ﬂuoxetine
dose, co-medication, PK/PD data or other relevant outcomes
such as odd ratio (OR) or relative risk (RR), and metabolic
proﬁles of participants. Studies were categorised based on
their study design: (1) experimental studies, (2) observa-
tional studies or (3) case reports. If the study was performed
in a way that researchers intentionally gave the combina-
tion of metoprolol-paroxetine/ﬂuoxetine to healthy
volunteers/patients in order to observe its outcomes, the
study was regarded as an experimental study. However, if re-
searchers only observed the effects of the interaction from
the patients with/without the combination without doing
any intervention or modiﬁcation, the study was included
as an observational study. Lastly, if the article was a detailed
scientiﬁc report regarding a single observation about the
clinical outcome of the interaction, it was included as a
case report.
Quality assessment of included articles
To assess the quality of the studies included in this systematic
review, we used the Joanna Briggs Institute critical appraisal
tools for assessing the methodological quality of case reports,
randomized clinical trials, quasi-experimental studies, and
observational studies (case control and cohort studies) [21].
Additionally, we used the National Heart, Lung, and Blood In-
stitute quality assessment tool for assessing the quality of a
before-after study with no control group [22]. The complete
list of questions from each tools can be found in the
Supporting Information Data S2.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked
to corresponding entries in http://www.guidetopharmaco-
logy.org, the common portal for data from the IUPHAR/BPS
Guide to PHARMACOLOGY [23], and are permanently
archived in the Concise Guide to PHARMACOLOGY
2017/18 [24, 25].
Results
Database searches and record selection
The systematic literature search in Pubmed, Web of Science,
Cochrane library, and Embase resulted in 354, 249, 81 and
894 records respectively. After removal of duplicates
(n = 262), 1316 unique records were selected for title and
abstract screening. Title and abstract screening resulted in
44 eligible records of which the full texts were evaluated. Full
text evaluation led to the exclusion of 35 publications
because no metoprolol and paroxetine/ﬂuoxetine combina-
tions were reported (n = 27), no clinical outcomes were re-
ported (n = 5), and they were not original studies (n = 3)
(Figure 1). A full overview of the included studies and charac-
teristics is shown in Table 1. The percentage of agreement
between reviewers for titles and abstracts screening was 98%
with kappa value 0.68 (good) [26]. Meanwhile, the percent-
age of agreement for full text screening was 97% with kappa
value 0.93 (very good) [26].
Characteristics of included studies
Experimental studies. We found four experimental studies on
the relevant combinations. Two of these studies were
performed in healthy volunteers and used a prospective
open-label, randomized, crossover study design [27, 28].
One study was also conducted in healthy participants but
used an open trial with pre- and post-design (without a
control group) [29]. The fourth study was a nonrandomized
intervention study (pre-and post-design with a reference
group) performed in patients with acute myocardial
infarction [30]. The distribution of characteristics of each
study can be viewed in Table 1.
Observational studies. Two observational studies were
included. The ﬁrst one was a nested case–control study
performed by Kurdyak et al. using a study population of
Ontario residents with a minimum age of 66 years who were
using metoprolol (332 254 patients) [31]. The cases were
metoprolol users who were hospitalized due to bradycardia
and newly treated either with a CYP2D6 inhibitor (ﬂuoxetine/
paroxetine) or with a non-potent CYP2D6 inhibitor
(ﬂuvoxamine/citalopram/venlafaxine/sertraline) (99 patients).
Meanwhile, the control group consisted of metoprolol users
without hospitalization and who were newly treated with the
studied drugs (394 patients). The second study is a
retrospective cohort study by Bahar et al. using a prescription
database (IADB.nl) among Dutch elderly (≥60 years) patients
with metoprolol prescription (64578 patients) who were co-
prescribed with paroxetine/ﬂuoxetine (528 patients), with
citalopram (673 patients), and with mirtazapine (625
patients) [32]. No PK data were presented in these studies.
Case reports. Three case reports were included in this
systematic review [18, 19, 33]. The ﬁrst case report concerned
a 63-year-old woman who was known with depression and
hypertension. The patient received paroxetine andalprazolam
for one year after which metoprolol was added to the treatment
regimen [33]. A second case report concerned a 54-year-old
depressed man with angina. Initially only metoprolol
was prescribed. Fluoxetine was added one month later to
treat his depression [19]. The last case study reported a case of a
62-year-old female patient diagnosed with hypertrophic
cardiomyopathy, bipolar disorder and depression, who received
both metoprolol and paroxetine [18]. None of the case reports
presented PK data.
Pharmacokinetic data
Experimental studies. All experimental studies showed
signiﬁcant increases in metoprolol exposure, as measured in
the area under the concentration curve (AUC) [27–30]
(Table 2). Hemeryck et al. reported signiﬁcant increases of
metoprolol PK parameters when combined with paroxetine.
During the combination treatment, the mean [S] and [R]-
metoprolol AUCs were ﬁve and seven times higher,
respectively, than with treatment with metoprolol alone
M. A. Bahar et al.
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[29]. Stout et al. reported approximately three-fold increase in
the [S]-metoprolol AUC, regardless of the metoprolol dosage
forms [27]. Furthermore, a study by Parker et al. showed
comparable results that paroxetine increased the [S]-
metoprolol AUC about three-fold, regardless of the
metoprolol formulations and doses [28]. The last two
studies showed that the [S]/[R] AUC ratios of metoprolol
were signiﬁcantly decreased after paroxetine intake in the
range of 27 to 30%. These results indicate that paroxetine
inhibition was greater in [R] than [S] metoprolol causing a
loss of stereoselective metoprolol metabolism. Finally,
Goryachkina et al. reported a four-fold increase of the total
metoprolol AUC when it was combined with paroxetine
[30]. Moreover, metoprolol metabolite concentration was
signiﬁcantly decreased by 77% [30].
Pharmacodynamic data
Experimental studies. The evaluation of the PD outcomes of
the experimental studies showed comparable results.
Hemeryck et al. found an increase in β1-blocking effects of
metoprolol after paroxetine administration. The β1-blocking
effect of metoprolol at different time points (before and after
paroxetine treatment) was deﬁned as the percentage of
change in the heart rate and systolic blood pressure
compared to the baseline (before metoprolol administration)
in a 4-min exercise test. Concomitant paroxetine
administration enhanced the reduction of exercise-induced
heart rate and systolic blood pressure by 46% and 97%,
respectively [29]. Similar effects on the β1-blocking capacities of
metoprolol were found by Parker et al. Yet, the study reported
the area under the effect time curve (AUEC) for both the
exercise-induced heart rate and systolic blood pressure
responses from 0–24 h after each metoprolol doses/
formulations administrations to determine the total β1-blocking
effect before and after paroxetine co-administration [28].
Paroxetine signiﬁcantly reduced the exercise heart rate AUEC in
patients treated with immediate-release metoprolol (metoprolol
IR), extended-release metoprolol (metoprolol ER) 100 mg, and
metoprolol ER 200 mg by 12%, 8.6% and 9.5%, respectively. In
addition, paroxetine signiﬁcantly decreased the exercise systolic
pressure AUEC in patients treated with metoprolol IR,
metoprolol ER 100 mg, and metoprolol ER 200 mg by 7.5%,
9.2%, and 11%, respectively. No signiﬁcant differences were
found between patients treated with the different formulations
in systolic blood pressure or heart rate AUEC [28].
Stout et al. reported only limited PD outcomes. A compar-
ison of the resting systolic blood pressure between metopro-
lol only and metoprolol/paroxetine phases showed that
paroxetine was able to signiﬁcantly alleviate themean resting
systolic blood pressure by approximately 7.3%. No differ-
ences were found in the pharmacodynamic outcomes from
the different metoprolol formulations [27].
Goryachkina et al. reported a signiﬁcant decrease in rest-
ing heart rates in the study group after the addition of
Figure 1
Flow diagram literature search and screening process
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paroxetine, with the heart rate AUEC decreasing by 13%.
Moreover, this decrease was not observed in the metoprolol
only group. They reported that there were two patients need-
ing a dose adjustment of metoprolol because they developed
severe postural hypotension and bradycardia. Both patients
had one inactive allele of CYP2D6. No physical exertion tests
were performed in this study because such tests were not part
of the standard clinical management of acute myocardial
infarction (AMI) patients [30].
Case–control study. Within the metoprolol receiving cohort,
Kurdyak et al. observed 8232 cases that were hospitalised due
to bradycardia. Of the 8232 hospitalised cases, 99 patients
were found to be newly treated with an SSRI within the
30 days prior to hospitalisation. Paroxetine or ﬂuoxetine
was prescribed in 23 of these cases (23.2%). No evidence for
an increased risk for bradycardia was found in this study
(OR 1.01; 95% CI 0.53–1.94, P = 0.98) [31].
Case reports. All case reports presented patients with cardiac
adverse events after concomitant use of metoprolol and
paroxetine/ﬂuoxetine. Two studies reported the emergence
of bradycardia (36 bpm and 41 ppm) [18, 19, 33]. Moreover,
one case presented a complete atrioventricular block that
was attributed to the DDI [33]. In the report by Walley et al.,
the heart rate returned to normal after discontinuation of
ﬂuoxetine. Moreover, no bradycardia was observed after
ﬂuoxetine rechallenge without concomitant metoprolol use
[19]. In the case presented by König et al., bradycardia
persisted even after a reduction of the metoprolol dose
(50 mg/day to 25 mg day1). It was therefore decided to
discontinue metoprolol, which resulted in a normalisation
of the heart rate [18].
Onalan et al. described a patient that presented with a
complete AV block while being treated with both metopro-
lol and paroxetine. The patient had been transferred to
their clinic because she was being considered for a perma-
nent pacemaker. Because a possible DDI was suspected, par-
oxetine and metoprolol were discontinued. Five days after
paroxetine and metoprolol discontinuation, the AV block
was completely recovered. Rechallenge with unchanged
doses of metoprolol or paroxetine only did not induce bra-
dycardia [33].
Other relevant outcomes
A cohort study by Bahar et al. used two proxy outcomes, early
discontinuation and dose adjustment of metoprolol, as
indicators of the appearance ofmetoprolol-related side effects
after the start of paroxetine/ﬂuoxetine in metoprolol
prescription. The study had no information on pharmacoki-
netics and pharmacodynamics parameters of metoprolol.
Compared to the metoprolol-citalopram combination,
metoprolol-paroxetine/ﬂuoxetine was not signiﬁcantly cor-
related with the early discontinuation (OR = 1.07, 95%
CI:0.77–1.48) and dose adjustment of metoprolol (OR = 0.87,
95% CI:0.57–1.33). However, because of the reported weak
inhibitory capacity of citalopram on the metabolic activity
of CYP2D6, the authors suggested a second comparator,
mirtazapine-metoprolol [16, 34, 35]. The comparison of the
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Table 2
Overview of the clinical outcomes per study
Reference
Clinical outcomes interaction
CYP2D6 proﬁlePharmacokinetics Pharmacodynamics Other outcomes
O. Onalan
et al. [33]
n/a Complete AV-Block n/a n/a
T. Walley
et al. [19]
n/a Bradycardia, lethargy n/a n/a
F. König
et al. [18]




IR (270%, P < 0.001),
↑mean AUC [R]-metoprolol
IR (419%, P < 0.001),
↑mean AUC [S]-metoprolol
ER (246%, P < 0.001),
↑mean AUC [R]-metoprolol
ER (334%, P < 0.001),
↓[S]/[R]-ratio




pressure (7.3%, P < 0.001)
no changes in HR or P-R
interval observed between






IR (209%, P < 0.05)
↑mean AUC [R]-metoprolol
IR (288%, P < 0.05)
↑mean AUC [S]-metoprolol
100 mg ER (220%, P < 0.05)
↑mean AUC [R]-metoprolol
100 mg ER(220%, P < 0.05)
↑mean AUC [S]-metoprolol
200 mg ER (210%, P < 0.05)
↑mean AUC [R]-metoprolol
200 mg ER (297%, P < 0.05)
↓[S]/[R]-ratio metoprolol
IR (27%, P < 0.05)
↓[S]/[R]-ratio metoprolol
100 mg ER (27%, P < 0.05)
↓[S]/[R]-ratio metoprolol
200 mg ER (27%, P < 0.05)
↓AUEC exercise HR IR
formulation (12%, P < 0.05),
↓AUEC exercise HR 100 mg
ER (8.6%, P < 0.05),
↓AUEC exercise HR 200 mg
ER (9.5%, P < 0.05),
↓AUEC exercise systolic
blood pressure IR
formulation (7.5%, P < 0.05),
↓AUEC exercise systolic
blood pressure 100 mg
ER (9.2%, P < 0.05),
↓AUEC exercise systolic
blood pressure 200 mg
ER (11.1%, P < 0.05)
n/a CYP2D6*1/*1 (n = 3),
CYP2D6*1/*2 (n = 4),
Other [at least 1 active




(408%, P < 0.001),
↑mean AUC [R]-metoprolol
(693%, P < 0.001)
↑AUEC reduction in exercise HR
(46%, P < 0.01)b
↑AUEC reduction in exercise
systolic blood pressure






(321%, P < 0.0001),
↓mean AUC
α-hydroxy-metoprolol
(77%, P < 0.0001),
↓AUEC resting HR





[<45 BPM] (n = 1)a
n/a CYP2D6*1/*1 (n = 9),





n/a Compared to ﬂuvoxamine,
citalopram, and venlafaxine,
-metoprolol: Bradycardia
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that metoprolol-paroxetine had a signiﬁcant correlation with
the early discontinuation of metoprolol (OR = 1.43, 95%
CI:1.01–2.02) but not the dose adjustment of metoprolol
(OR = 1.00, 95% CI:0.65–1.54) [32].
Co-medication
Co-medication might be a source of additional drug–drug in-
teractions with both metoprolol and paroxetine/ﬂuoxetine.
As far as reported, the inﬂuence of co-medication in the pub-
lications included in this review was limited. In the two cases
reports, Onalan et al. and König et al. reported that beside the
combination of metoprolol and paroxetine, patients were co-
medicated with alprazolam and lithium, respectively. Both
drugs have no PK/PD interaction with either metoprolol or
paroxetine [36, 37]. In a study reported by Goryachkina
et al., some patients with the metoprolol-paroxetine combi-
nation were using other drugs (Table 1). These drugs also
have no clinically signiﬁcant interaction either with meto-
prolol or paroxetine, with an exception for the combination
of acetylsalicylic acid with paroxetine [37, 38]. This interac-
tion increases the risk of gastrointestinal bleeding [38–43].
Therefore, it is recommended to prescribe proton pump
inhibitors to manage this interaction [44, 45].
Quality assessment of included studies
The RCT studies did not give sufﬁcient information about the
procedure of randomization and allocation concealment.
Both of the randomized studies were open trials, therefore,
no blinding procedures were used. For the pre-post study
without reference group, there is a low risk of bias based on
the question list of the assessment tool. However, the study
has only limited sample size, and due to the lack of a control
group, the validity of the results might be questioned. The
quality assessment of the quasi-experimental study revealed
a low risk of bias. The presence of the reference group in this
study design was expected to increase validity of the results.
However, the treatment and control groups in the study were
not comparable because these concerned different clinical
conditions. The treatment group consisted of patients with
AMI developing depression, whereas the control group only
consisted of patients with AMI. Lastly, both observational
studies carried a low risk of bias. All the case reports demon-
strated the characteristics, clinical conditions, the medical
history, the intervention and the adverse events sufﬁciently.
However, none of them described the family history of the
patient including their genetic information. The complete re-
sults of the quality assessment of included studies can be seen
in Table 3.
Discussion
Here we present a systematic review that addressed the PK, PD
and clinical relevance of the metoprolol and paroxetine/
ﬂuoxetine interaction. We found nine studies that provided
information on the impact of this DDI. The experimental
studies and case reports indicated that the DDI may cause
important clinical effects. However, the results from the
observational studies were conﬂicting. The only case control
study showed that metoprolol-paroxetine/ﬂuoxetine was
not signiﬁcantly associated with bradycardia. Meanwhile, a
cohort study indicated that the combination is signiﬁcantly
associated with an early discontinuation of metoprolol. The
current conﬂicting evidence arising from these single studies
regarding the clinical effect of the interaction may have be-
come one of the underlying reasons for the frequent co-
administration of the combination in clinical practice [8].
Due to the limited number of cases and the lack of
pharmacokinetic data, the case reports seem not to provide
sufﬁcient evidence to make a clear statement about the
clinical relevance of the combination [18, 19, 33]. However,
conclusions from the case reports were further supported by





CYP2D6 proﬁlePharmacokinetics Pharmacodynamics Other outcomes
dose adjustment of





of metoprolol (OR = 1.43,
95% CI 1.01–2.02);
dose adjustment of
metoprolol (OR = 1.00,
95% CI 0.65–1.54)
AUC, Area under the Concentration Curve; AUEC, Area under the Effect Curve; BPM, Beats per minute; ER, Extended Release; HR, Heart Rate;
IR, Immediate Release; MR, Metabolic Ratio; OR, Odds Ratio.
aPatient carrying one non-functional CYP2D6 allele.
b% change from the baseline (before metoprolol intake) in 4-min exercise tests.
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was reported to signiﬁcantly increase metoprolol exposure
(three to ﬁve-fold increase of [S]-metoprolol AUC) and reduce
the heart rate and systolic blood pressure of patients, both in
rest and exercise state. Although no experimental studies
used ﬂuoxetine, we assume that the impact of the interaction
is comparable. Paroxetine and ﬂuoxetine have an
equipotent inhibitory capacity on CYP2D6 metabolic
activity (Ki value = 0.15 microM and 0.60 microM, respec-
tively) [16]. Moreover, the major metabolite of ﬂuoxetine,
norﬂuoxetine, was also reported to have an equal inhibitory
potency on CYP2D6 (Ki = 0.43 microM) [16]. The combina-
tion may therefore trigger clinically relevant adverse events.
The loss of stereoselective metabolism of metoprolol was
also found in the experimental studies. CYP2D6 has been
shown to preferentially metabolise the inactive [R]-enantio-
mer [30]. Therefore, the inhibition of metoprolol metabolism
by paroxetine/ﬂuoxetine might cause [R]-enantiomer
concentrations to increase more than those of the [S]-
enantiomer, as suggested by the decreased [S]/[R] AUC ratios
[27–29]. Since the [R]-enantiomer has a lower afﬁnity and
selectivity for the β-1 receptor, a relative increase of this enan-
tiomermight lead to a loss of cardio-selectivity [27]. However,
only few metoprolol related non-cardiac side-effects were re-
ported, with the exception of fatigue, nausea, drowsiness,
sleepiness, and diarrhea, which might be also related to par-
oxetine pharmacodynamic effects [27–29]. Metoprolol is
available in IR and ER preparations. There were no clinically
signiﬁcant differences in the interaction with paroxetine
between the IR and ER preparations.
The conﬂicting impact of the combination is illustrated
by the observational studies [31, 32]. Kurdyak et al. reported
that no increased risk of bradycardia in patients with the
combination. However, the study has several limitations
because it has no data on PK, drug dose, and heart rates.
Moreover, the study did not control for mild inhibitory
effects of citalopram and ﬂuvoxamine, which were included
in the reference group, on CYP2D6 [16, 34, 35, 46–48]. It
may inﬂuence the outcome of interaction especially in a
senior population because of physiological changes due to
the aging process. Additionally, citalopram has been
associated with an increased risk of bradycardia particularly
in the elderly population [49–53]. The risk might be even
higher in elderly patients with cardiovascular problems who
are treated with metoprolol. Finally, the statistical power of
the study was relatively low which led to a very wide
conﬁdence interval.
Bahar et al. tried to avoid the confounding effect of the
weak inhibitory activity of citalopram on CYP2D6 and its
potential bradycardia inducing effect by offering an alterna-
tive comparison mirtazapine-metoprolol [32]. Mirtazapine is
an atypical antidepressant which has no interaction with
metoprolol [34, 54]. They found that the metoprolol and
paroxetine/ﬂuoxetine combination confers a signiﬁcant
43% higher risk of early discontinuation of metoprolol, but
not dose adjustment of metoprolol. It seems that medical
doctors tend to stop the use of metoprolol instead of
adjusting its dose when there is an emergence of
metoprolol-related side effects. However, their study is not
without limitation. They used a prescription database which
does not have any PK and PD information on metoprolol.
They only used proxy outcomes to indicate the emergence
of metoprolol-related side effects. A prescription database
only records the information from the prescription which
may not reﬂect the real situation of the patients, for example,
whether they take their drugs as prescribed. Another limita-
tion was that they only used the name of drugs for treating
certain diseases as a proxy for the comorbidities which may
cause the early discontinuation of metoprolol.
Both observational studies have also another important
limitation. They did not have any information regarding
Table 3
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the phenotype of CYP2D6 which may inﬂuence the
magnitude of the DDI [32]. Metoprolol metabolism is greatly
dependent on the CYP2D6 phenotype status [55, 56]. There-
fore, the potential effect on certain risk populations might be
ignored, as can be seen from a study by Goryachkina et al.
They reported that two of their patients, who had one non-
active CYP2D6 allele, experienced postural hypotension and
excessive bradycardia during the use of the metoprolol-
paroxetine combination, and therefore required a dose
adjustment of metoprolol. Meanwhile, other participants
with the normal metabolizer (NM) genotype of CYP2D6 did
not experience the side effects [30]. It has been reported that
patients with less active CYP2D6 enzyme are more prone to
experiencing a phenoconversion to poor metabolizer (PM)
CYP2D6 than patients with a fully active enzyme after
administration of a strong CYP2D6 inhibitor. Moreover, apart
from its potent CYP2D6 inhibitory capacity, paroxetine itself
is also metabolized by CYP2D6. Therefore, the concentration
of paroxetine that is available to inhibit the activity of a lower
metabolic activity of CYP2D6 is higher in the patients
with CYP2D6 intermediate metabolizer (IM) than NM
genotype [57].
The identiﬁcation of susceptible patient populations
should be the ﬁrst step towards clinical management guide-
lines. Patients with deviating genotypes such as PM, IM or
ultra-rapid metabolizer (UM) genotypes for CYP2D6 might
experience a different magnitude of DDI compared to those
with NM [58]. Therefore, genotype and phenotype informa-
tion of the patients are important factors to be considered
in the management of DDI. The prevalence of deviating
CYP2D6 genotypes in Caucasians is 3 to 5% UM, 10 to
17% IM and 5 to 10% PM [59, 60]. In addition, patients
that are more susceptible for the side effects of increased
β-blockade, such as elderly patients with bronchospastic
disease or with a poor left ventricular systolic function have
been suggested to be at higher risk for the interaction [28].
Bahar et al. also reported that female elderly patients with
the interacting combination have a signiﬁcantly 62%
higher risk for early discontinuation of metoprolol com-
pared to those without the DDI. This difference was not
observed in male elderly patients. The authors explained
that it might be caused by differences in the body mass
index and the rate of CYP2D6 metabolic activity between
men and women. However, the data regarding the latter is
not clear [32].
Furthermore, other safer SSRIs with comparable effective-
ness could be used instead of paroxetine/ﬂuoxetine in
depressed patients that are on metoprolol [61]. Patients that
are started on concomitant metoprolol and paroxetine/
ﬂuoxetine therapy should be carefully monitored, at least
during the ﬁrst few weeks of the treatment, to allow timely
intervention if a signiﬁcant hypotension or bradycardia
starts to occur.
The strength of our study is that we used a systematic
search strategy to include all published articles without any
language restrictions in four databases. Therefore, we
included all published evidence available regarding the clini-
cal impact of the combination. The limitation of this current
study is that we cannot perform meta-analysis of the data
since the studies had different characteristics. Hence, we only
provide a description of the result of the included studies,
and quantiﬁcation of effects was based on single overall
study results.
In conclusion, despite the conﬂicting evidence, most of
the studies indicate that the DDI have a signiﬁcant clinical
impact. More research is required to determine the clinical
impact of difference in CYP2D6 phenotype on themagnitude
of metoprolol-paroxetine/ﬂuoxetine combination. The
studies should include more patients with genotype and
phenotype information and should have complete PK and
PD data. Since alternative and safe antidepressants and beta-
blockers are available, it is prudent to avoid the concurrent
use of metoprolol and paroxetine/ﬂuoxetine. Nonetheless,
if the prescription of the combination is unavoidable, a does
adjustment or a close monitoring of metoprolol-related side
effects is necessary.
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